动性心房动的切除:在现在和未来之间
Antonio Gianluca Robles1,2, Zefferino Palamà1,3, Antonio Scarà4
1Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Reviews in cardiovascular medicine
|July 30, 2024
概括
肺静脉隔离 (PVI) 是心房动 (AF) 的黄金标准. 本综述详细介绍了20多年来 Paroxysmal AF 切除技术和理解的演变.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 医疗技术 医疗技术 医学技术
背景情况:
- 肺静脉隔离 (PVI) 是心房动 (AF) 的已确立基石.
- 目前的指导方针承认PVI是首次AF移除的黄金标准,无论AF类型 (发发性或持续性).
- 自1998年以来,方法和技术的进步已经完善了PVI程序.
研究的目的:
- 在过去的二十年里,描述帕洛西斯马耳心肌移除的演变.
- 专注于现有的技术和对阳性AF产生机制的理解.
- 探索AF治疗的量身定制方法的潜力,并提供未来的前景.
主要方法:
- 对科学文献和临床指导方针的审查关于AF消去.
- 分析历史和当前的PVI方法和技术.
- 讨论机械的洞察力,对帕洛西斯的AF.
主要成果:
- 对于AF切除,PVI仍然是黄金标准.
- 自1998年以来,PVI技术和技术发生了显著的变化.
- 对 Paroxysmal AF 机制的越来越多的理解支持量身定制的治疗策略.
结论:
- PVI已经经历了实质性的演变,提高了它的有效性.
- 更深入的机理性理解有助于个性化AF切除方法.
- 未来的前景表明,AF治疗的创新仍在继续.
相关概念视频
Disturbances in Heart Rhythm
927
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
927
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
952
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
952
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
812
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
812
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
727
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
727
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K


